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A b s t r a c t
Introduction: Radical endoscopic minimal-invasive treatment methods, such as thermal ablation, are sought as an
alternative to standard radical surgical treatment of kidney neoplasms. We analysed patients who could be qualified
for radical treatment due to T1a renal tumour.
Material and methods: Twenty-three patients out of 129 who underwent radiofrequency thermal ablation of kidney
tumours in the years 2003-2010 were analysed. The inclusion criteria were age below 70 years, lack of major comor-
bidities (ASA score 1, 2), and competent contralateral kidney. In all cases tumour size was below 4 cm. All patients
were followed up with computed tomography (CT) and ultrasonography (USG) every 6 months for 3 years.
Results: In 20 patients kidney tumour was biopsied before radiofrequency ablation (RFA) and 10 of these biopsies were
positive and revealed cancer. Six patients required additional treatment due to recurrence visible in CT – 3 with a pos-
itive biopsy result, 1 with negative and 2 without biopsy. Three of them were treated with a second session of RFA, 
1 with radical nephrectomy and 2 with partial nephrectomy. No disease dissemination was observed and all patients
who received additional treatment remain disease free.
Conclusions: The RFA can be safely used in selected patients with T1a tumour as an alternative to partial nephrecto-
my. Careful follow-up is required after thermal ablation and allows early detection and successful treatment of recur-
rences. 
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Introduction
Radiofrequency ablation (RFA) is a treatment
method that utilizes radiofrequency alternating cur-
rent to ablate tissue around the needle electrode.
Over the last 10 years, this technique has been gain-
ing popularity in several fields of oncological surgery
[1-3]. The introduction of RFA into other fields of sur-
gery has fuelled the interest to study its application
in treatment of small renal masses (SRM), less than
4 cm. Some controversies remain, however, regarding
its oncological efficacy. The RFA is a minimally inva-
sive therapeutic modality for renal tumours. It can be
an alternative to nephrectomy in patients with single
kidney, bilateral tumours, von Hippel-Lindau disease
and in those with contraindications for surgery [4-6].
The aim of this paper is to present our experiences
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with application of RFA in patients who could be
qualified for nephron-sparing surgery (NSS) due to
T1a kidney tumours.
Material and methods
Twenty-three patients out of 129 who underwent
RFA in the years 2003-2010 were retrospectively
analysed. The inclusion criteria were age below 70
years, lack of major comorbidities (ASA score 1 or 2),
and competent contralateral kidney (Table I).
Tumours were qualified based on computed tomog-
raphy (CT) and all were staged as T1a (average size
2.6 ±0.5 cm). Pre-treatment biopsy was performed.
Ultrasound-guided RFA was performed using alter-
nating current (460 kHz) conducted directly to the
tumour with a needle electrode. Patients were fol-
lowed according to guidelines prepared for NSS.
No. Age ASA Initial Tumour Pre-treatment Re-treatment Final histology Follow
[years] score creatinine size [cm] biopsy up 
[μmol/l] [months]
1 60 2 84 2.0 Indefinite 70
2 56 2 61 2.8 Indefinite 54
3 56 2 65 2.0 cRCC Radical surgery cRCC 52
4 50 1 99 2.5 Indefinite 50
5 46 2 80 2.7 Not assessed 43
6 52 2 45 3.4 Indefinite 40
7 60 1 88 2.9 Indefinite 39
8 60 2 53 2.5 cRCC 35
9 60 2 72 4.0 Indefinite 29
10 58 2 60 2.4 cRCC 28
11 37 1 57 2.0 cRCC NSS Necrosis 26
12 52 2 71 2.5 cRCC 17
13 50 2 70 1.0 cRCC 16
14 64 2 62 2.6 cRCC RFA 16
15 62 2 67 3.0 Not assessed RFA 15
16 63 2 71 3.0 Indefinite RFA 14
17 68 2 77 1.8 Indefinite NSS Oncocytoma 13
18 70 2 81 1.5 Indefinite 11
19 64 2 70 3.4 cRCC 11
20 62 2 62 4.0 cRCC 6
21 55 2 74 2.5 Not assessed 6
22 58 1 84 3.0 Cancer cells 6
23 47 2 43 2.3 Indefinite 5
Table I. Patients undergoing radiofrequency ablation (RFA) due to small renal masses 
cRCC – clear cell type renal carcinoma, NSS – nephron-sparing surgery
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Results
In 20 of 23 patients the tumour was successfully
biopsied before RFA and 10 of these biopsies were
positive and revealed cancer. Six patients required
additional treatment due to recurrence visible in CT –
3 with a positive biopsy result, 1 with negative and 
2 without biopsy. Three of them were treated with
a second session of RFA, 1 with radical nephrectomy
and 2 with partial nephrectomy (Table I). No disease
dissemination was observed and all patients who
received additional treatment due to recurrence
remain disease free. Average follow-up time was 
2 years (5 months to 5.8 years). 
Discussion
While RFA allows ablative success to be achieved,
it requires acceptance of re-treatment necessity in
a certain percentage of cases. Although the recur-
rence risk after RFA is higher in comparison to radical
nephrectomy, early detection with an appropriate fol-
low-up often allows successful treatment with an
additional RFA session or partial nephrectomy. In cer-
tain cases radical nephrectomy is required. Most of
the patients retain their kidney and remain disease
free. In our experience, the recurrence risk did not
influence the survival or progression rate.
It must also be stressed that RFA is a minimally
invasive treatment which can even be performed
under local anaesthesia and is connected with short-
er hospital stay than NSS or even laparoscopic
nephrectomy. Complications after RFA are less fre-
quent and they are more often minor in comparison
to surgical series [4, 7]. These facts render RFA an
attractive minimally invasive treatment for SRM,
which can be offered instead of partial nephrectomy
[4]. The study cohort was small because of specific
inclusion criteria – such patients should, according to
guidelines, undergo NSS, while RFA is mainly recom-
mended for older ones with serious comorbidities.
An important issue to be resolved is an informa-
tive and appropriately performed renal tumour biop-
sy (RTB). The RTBs gained popularity in the evalua-
tion of SRM because imaging alone is insufficient to
assess the underlying tumour aggressiveness. The
complication rate was low, and neoplasm seeding
along the needle track has been reported to be
extremely rare [8]. A certain disadvantage of RTB is
a considerable, although improving over time, per-
centage of ‘indefinite’ biopsy results. The RTB is rec-
ommended to help differentiating benign from
malignant SRM prior or during ablative therapies and
in follow-up, especially after RFA [6-8]. 
The RFA was planned based on computed tomog-
raphy examination prior to treatment while the pro-
cedure itself was performed under USG guidance.
Effectiveness of US-guided RFA is reported to be
comparable with CT-guided RFA results [9]. The RFA is
safe and effective in renal tumours; corticomedullary
lesions and tumours > 3 cm, however, are associated
with an increased probability of incomplete ablation.
In tumours > 5 cm, RFA has a significant failure rate
[7]. The RFA provided successful treatment of SRM
with a low recurrence rate as well as prolonged
metastasis-free and cancer-specific survival rates at
5 years after treatment [5].
Conclusions
It seems that RFA can be safely performed in
selected patients with T1a tumour as an alternative
to partial nephrectomy. The tumour should be biop-
sied prior to RFA. Careful follow-up, similar to the one
after NSS, is required after thermal ablation and
allows early detection and successful treatment of
recurrences.
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